Alumis is a clinical stage biopharmaceutical company focused on Tyrosine Kinase 2 (TYK2) inhibitors, ESK-001, a second-generation inhibitor maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. We show 3 historical shares outstanding datapoints in our ALMS shares outstanding history coverage, used to compute ALMS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALMS market cap history over the course of time is important for investors
interested in comparing ALMS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALMS versus a peer is one thing; comparing
ALMS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALMS can fluctuate over the course of history.
With this page we aim to empower investors researching ALMS by allowing them to research the ALMS market cap history. |
Free ALMS Email Alerts:
Video: The Importance of Market Cap
